CoChat

MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array

Albiges, Laurence, Guegan, Justine, Le Formal, Audrey, Verkarre, Virginie, Rioux-Leclercq, Nathalie, Sibony, Mathilde, Bernhard, Jean-Christophe, Camparo, Philippe, Merabet, Zahira, Molinie, Vincent, Allory, Yves, Orear, Cedric, Couvé, Sophie, Gad, Sophie, Patard, Jean-Jacques, Escudier, Bernard · 2014 · Clinical Cancer Research
Cited by 176

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Purpose: Papillary renal cell carcinomas (pRCC) are the most common nonclear cell RCC subtype. Germline mutations of the MET oncogene at 7q31 have been detected in patients with hereditary type I pRCC and in 13% of sporadic type I pRCC. Recent report of MET inhibition strengthened the role of c-Met inhibition across pRCC. Experimental Design: We collected 220 frozen samples of sporadic pRCC through the French RCC Network and quality controlled for percentage of malignant cells >70%. Gene expression was assessed on 98 pRCC using human whole-genome Agilent 8 × 60K arrays. Copy number alterations were analyzed using Agilent Human 2 × 400K and 4× 180K array for type II pRCC and comparative genomic microarray analysis method for type I pRCC. MET gene sequencing was performed on type I pRCC. Results: MET expression level was high across all pRCC. We identified copy number alterations (gain) in 46% of type II pRCC and in 81% of type I pRCC. Correlation between DNA copy number alterations and mRNA expression level was highly significant. Eleven somatic mutations of MET gene were identified amongst 51 type I pRCC (21.6%), including 4 new mutations. We validated LRRK2 cokinase as highly correlated to MET expression. Conclusion: The present report expands the role of MET activation as a potential target across all pRCC subtypes. These data support investigating MET inhibitors in pRCC in correlation with MET activation status. Clin Cancer Res; 20(13); 3411–21. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-2173

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 176

Metadata

Authors
Albiges, L., Guegan, J., Le Formal, A., Verkarre, V., Rioux-Leclercq, N., Sibony, M., Bernhard, J.-C., Camparo, P., Merabet, Z., Molinie, V., Allory, Y., Orear, C., Couvé, S., Gad, S., Patard, J.-J., & Escudier, B.
Venue
Clinical Cancer Research
Published
2014-06-30
Volume
20
Issue
13
Pages
3411-3421
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2146810218
Cited by
176
References
36
FWCI
14.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2173
The paper
Albiges, L., Guegan, J., Le Formal, A., Verkarre, V., Rioux-Leclercq, N., Sibony, M., Bernhard, J.-C., Camparo, P., Merabet, Z., Molinie, V., Allory, Y., Orear, C., Couvé, S., Gad, S., Patard, J.-J., & Escudier, B. (2014). MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2173

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.